Clinical Study Number | 1188.1 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
A double-blind (at each dose level), randomised, placebo-controlled single increasing dose safety, tolerability and preliminary pharmacokinetics study in healthy male volunteers after oral administration of BILR 355 BS solved in PEG 400 (dosage: 1 - 200 mg) |
Study Document | Trial synopsis 1188.1 english |
Clinical Study Number | 1188.10 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Pharmacokinetic Interaction Study of BILR 355 BS Plus Ritonavir with Truvada |
Study Document | Trial synopsis 1188.10_CO english |
Clinical Study Number | 1188.2 |
---|---|
Study Indication | HIV Infections |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Randomized Placebo Controlled Dose Escalation Study of Safety, Tolerability Pharmacokinetics and Efficacy of BILR 355 BS in Healthy Volunteers and HIV-Infected Subjects |
Study Document | Trial synopsis 1188.2_CO english |
Clinical Study Number | 1188.32 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Open Label, Single Dose Escalation Trial of BILR 355 (SDS) Plus Ritonavir in Healthy Volunteers |
Study Document | Trial synopsis 1188.32_CO english |
Clinical Study Number | 1188.33 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Open Label Relative Bioavilability Study of Tablet and Capsules of SDS Formulations in Healthy Volunteers |
Study Document | Trial synopsis 1188.33_CO english |
Clinical Study Number | 1188.4 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
An open study to investigate the effect of two times oral 100 mg ritonavir capsules on pharmacokinetics of single doses of BILR 355 BS (dose steps: 5 and 12.5 mg) solved in 5 ml PEG 400 after oral administration in healthy male volunteers |
Study Document | Trial synopsis 1188.4 english |
Clinical Study Number | 1188.5 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Single Dose Relative Bioavailability of BILR 355 BS newTablet and suspension formulations compared to current 1b formulation |
Study Document | Trial synopsis 1188.5_CO english |
Clinical Study Number | 1188.6 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
An open study to investigate the effect of different boosting agents on pharmacokinetics of single doses of BILR 355 BS (dose steps: 5 and 12.5 mg) dissolved in 5 mL PEG 400 after oral administration in healthy male volunteers |
Study Document | Trial synopsis 1188.6 english |
Clinical Study Number | 1188.7 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Pharmacokinietic interaction trial between tipranivir plus ritonavir and BILR 355 BS |
Study Document | Trial synopsis 1188.7_CO english |
Clinical Study Number | 1188.8 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Trial of Pharmacokinetic Interaction between Lopinivir plus ritonavir and BILR 355 BS |
Study Document | Trial synopsis 1188.8_CO english |
Clinical Study Number | 1188.9 |
---|---|
Study Indication | Healthy |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | I |
Study Title |
Study of Pharmacokinetic Interaction between Combivir (ZDV+3TC) and BILR 355 BS plus ritaonavir |
Study Document | Trial synopsis 1188.9_CO english |
Clinical Study Number | 1188.31 |
---|---|
Study Indication | HIV Infections |
Product | BILR 355 |
Generic Name | BILR 355 |
Lab Code | |
Clinical Phase | IIa |
Study Title |
Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTVboosted BILR 355 (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen |
Study Document | Trial statement 1188.31 english |
Download our Policy on Transparency and Publication of Clinical Study Data.Download
Browse our clinical study overview and read study synopses and lay summaries.
Learn about our process of responsible sharing of clinical study data and documents and request access to data and documents.